 This randomised, double blind, placebo controlled, crossover trial will evaluate the effects of daily consumption of EstroSenseMD on estrogen profile in female subjects. 120 consenting women will be enrolled randomised to participate in this study. Potential subjects will be recruited by advertisements placed on notice boards around the university and at local naturopath clinics. Advertisements may also be placed in local newspapers. The study consists of four clinic visits. Individuals who are interested in participating will be asked to contact the study coordinator to schedule their first clinic visit Visit 1. At Visit 1 the participant will be given information about the study and be given an opportunity to ask about the study. Those women who are still interested in participating will be asked to sign a consent form. Once consent if obtained screening and baseline data collection will begin. If eligible, participants will be scheduled to return to the clinic 19-21 days after the beginning of their last or next menstruation for Visit 2. At Visit 2 baseline data collection will continue followed by random assignment to an intervention sequence. All participants will be given and instructed to consume 3 capsules per day of EstroSenseMD or Placebo for three menstrual cycles. After consuming the study intervention for 3 cycles, the participant will be asked to return to the clinic 19-21 days after the start of their third menstruation for Visit 3. At Visit 3 data will be collected and participants will be crossed over to the other treatment for three more cycles. After 3 menstrual cycles 19-21 days after the start of their third menstruation the participant will return to the clinic for Visit 4 for final data collection. Visit 4 marks the end of the study. Participants will also be provided with a diary throughout the study to record supplement use and any adverse events. 